Mccarter Private Wealth Services LLC Sells 445 Shares of Edwards Lifesciences Corporation $EW

Mccarter Private Wealth Services LLC reduced its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 0.9% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 46,950 shares of the medical research company’s stock after selling 445 shares during the period. Edwards Lifesciences accounts for approximately 2.2% of Mccarter Private Wealth Services LLC’s investment portfolio, making the stock its 17th biggest position. Mccarter Private Wealth Services LLC’s holdings in Edwards Lifesciences were worth $3,403,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Jennison Associates LLC raised its position in Edwards Lifesciences by 34.3% during the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company’s stock worth $731,036,000 after purchasing an additional 2,576,383 shares during the last quarter. Brown Advisory Inc. raised its position in Edwards Lifesciences by 7.6% during the 4th quarter. Brown Advisory Inc. now owns 8,155,355 shares of the medical research company’s stock worth $603,741,000 after purchasing an additional 575,699 shares during the last quarter. Deutsche Bank AG raised its position in Edwards Lifesciences by 10.4% during the 4th quarter. Deutsche Bank AG now owns 6,903,202 shares of the medical research company’s stock worth $511,044,000 after purchasing an additional 652,923 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Edwards Lifesciences by 8.5% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 6,519,257 shares of the medical research company’s stock worth $482,621,000 after purchasing an additional 513,468 shares during the last quarter. Finally, Northern Trust Corp raised its position in Edwards Lifesciences by 21.8% during the 4th quarter. Northern Trust Corp now owns 6,505,227 shares of the medical research company’s stock worth $481,582,000 after purchasing an additional 1,165,845 shares during the last quarter. 79.46% of the stock is owned by institutional investors.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the transaction, the vice president owned 22,002 shares in the company, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $75.23, for a total value of $673,308.50. Following the transaction, the insider owned 206,900 shares of the company’s stock, valued at $15,565,087. This trade represents a 4.15% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 24,584 shares of company stock worth $1,897,762. Insiders own 1.29% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on EW shares. Canaccord Genuity Group raised their target price on Edwards Lifesciences from $75.00 to $81.00 and gave the stock a “hold” rating in a research report on Friday, July 25th. Barclays increased their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday, July 25th. Piper Sandler increased their price target on Edwards Lifesciences from $83.00 to $90.00 and gave the stock an “overweight” rating in a report on Friday, July 25th. The Goldman Sachs Group reiterated a “buy” rating on shares of Edwards Lifesciences in a report on Friday, July 25th. Finally, Royal Bank Of Canada increased their price target on Edwards Lifesciences from $85.00 to $89.00 and gave the stock an “outperform” rating in a report on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $85.90.

Edwards Lifesciences Stock Performance

Shares of EW opened at $81.1580 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The stock has a 50-day moving average of $77.45 and a 200-day moving average of $74.60. The company has a market cap of $47.65 billion, a PE ratio of 11.68, a P/E/G ratio of 3.93 and a beta of 1.08. Edwards Lifesciences Corporation has a one year low of $64.00 and a one year high of $83.00.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.62 by $0.05. The company had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period last year, the business posted $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, equities research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.